Goldman Sachs’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History
Bought
Maintained
Sold
Other funds holding LABD
IC
CCM
CF
GS
Goldman Sachs's LABD Position: Q1 2026 in Review
Goldman Sachs opened a new position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2026: 59,208 shares worth $965K. The stake represents ﹤0.01% of the portfolio and ranks #5111 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in LABD as recently as Q3 2025.
Goldman Sachs first reported a position in LABD in Q2 2017 and has held it in 18 quarters since. The position peaked at $6.65M in Q3 2023. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.
- Goldman Sachs held 59,208 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $965K as of Q1 2026.
- Direxion Daily S&P Biotech Bear 3X ETF was a new Goldman Sachs position in Q1 2026.
- Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5111 holding.
- Goldman Sachs first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q2 2017 and has held it in 18 quarters since.
- Goldman Sachs's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $6.65M in Q3 2023.
- 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.